You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

~ Buy the XERMELO (telotristat etiprate) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR XERMELO

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for XERMELO

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03790111 ↗	A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer	Active, not recruiting	Lexicon Pharmaceuticals	Phase 2	2019-03-13	A Phase 2, multicenter, open-label, 2-stage study to assess the safety, tolerability, and efficacy of XERMELO in combination with first-line (1L) therapy (cisplatin [cis] plus gemcitabine [gem])
NCT03790111 ↗	A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer	Active, not recruiting	TerSera Therapeutics LLC	Phase 2	2019-03-13	A Phase 2, multicenter, open-label, 2-stage study to assess the safety, tolerability, and efficacy of XERMELO in combination with first-line (1L) therapy (cisplatin [cis] plus gemcitabine [gem])
NCT03910387 ↗	Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer	Recruiting	Lexicon Pharmaceuticals	Phase 2	2019-04-17	This phase II trial studies how well telotristat ethyl works in promoting weight stability in patients with pancreatic adenocarcinoma that has come back and spread to other places in the body. Telotristat ethyl may decrease bowel movements which may make patients gain weight. Stabilizing weight may help patients tolerate chemotherapy better and improve longevity.
NCT03910387 ↗	Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer	Recruiting	TerSera Therapeutics LLC	Phase 2	2019-04-17	This phase II trial studies how well telotristat ethyl works in promoting weight stability in patients with pancreatic adenocarcinoma that has come back and spread to other places in the body. Telotristat ethyl may decrease bowel movements which may make patients gain weight. Stabilizing weight may help patients tolerate chemotherapy better and improve longevity.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for XERMELO

Condition Name

Chart
Table

Condition Name for XERMELO
Intervention	Trials
Neuroendocrine Tumors	2
Stage III Pancreatic Cancer AJCC v8	1
Stage IV Pancreatic Cancer AJCC v8	1
Biliary Tract Cancer	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for XERMELO
Intervention	Trials
Neuroendocrine Tumors	3
Carcinoid Tumor	2
Carcinoid Heart Disease	1
Pancreatic Neoplasms	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for XERMELO

Trials by Country

Map
Table

Trials by Country for XERMELO
Location	Trials
United States	14
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for XERMELO
Location	Trials
Kentucky	2
Georgia	1
Texas	1
Oklahoma	1
North Carolina	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for XERMELO

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for XERMELO
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for XERMELO
Clinical Trial Phase	Trials
Recruiting	2
Not yet recruiting	1
Withdrawn	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for XERMELO

Sponsor Name

Chart
Table

Sponsor Name for XERMELO
Sponsor	Trials
Lexicon Pharmaceuticals	3
TerSera Therapeutics LLC	3
Aman Chauhan	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for XERMELO
Sponsor	Trials
Industry	7
Other	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.